Boehringer Ingelheim, a prominent research-focused biopharmaceutical company, has announced key changes to its board of managing directors. The Shareholders’ Committee has made the following adjustments:
Carinne Brouillon, who has been responsible for the human pharma business unit, will retire from the company effective October 1, 2024. Shashank Deshpande, currently overseeing the animal health business unit, will assume leadership of the human pharma division starting October 1, 2024. Deshpande joined the board on September 1, 2023.
Dr. Armin Wiesler, the regional managing director and head of animal health for Southeast Asia, Korea, Australia, and New Zealand, will join the board of managing directors effective October 1, 2024. He will take over from Shashank Deshpande in leading the animal health business unit.
Christian Boehringer, chairman of the Shareholders’ Committee, expressed gratitude to Carinne Brouillon: “We extend our sincere thanks to Carinne for her leadership and her efforts in evolving our human pharma business to ready it for our upcoming pipeline launches. Her positive attitude and patient-first approach have been deeply valued”.
Hubertus von Baumbach, chairman of the board of managing directors, commented: “We appreciate Shashank’s acceptance of his new role. His extensive board experience, leadership in key human pharma markets, and marketing expertise make him an ideal successor to Carinne. We also warmly welcome Armin to our board. His deep knowledge of the animal health sector and commercial acumen will support the continuation of the transformative work initiated by Shashank”.
Shashank Deshpande joined Boehringer Ingelheim in 2012 and has previously served as country managing director in Japan, along with holding various leadership and marketing positions in Japan and Germany. Deshpande has a Master’s degree in Business Administration from the University of Hamburg, Germany.
Armin Wiesler, who has been with the company since 2008, has held various local, regional, and global roles, including general manager in Thailand and positions at Boehringer’s US headquarters. He holds a Doctorate and a Master’s degree in Economics from the University of Freiburg, Germany.
Boehringer Ingelheim continues to focus on developing breakthrough therapies that aim to transform lives now and in the future, driven by innovation in areas of high unmet medical need.
Boehringer Ingelheim, a prominent research-focused biopharmaceutical company, has announced key changes to its board of managing directors. The Shareholders’ Committee has made the following adjustments:
Carinne Brouillon, who has been responsible for the human pharma business unit, will retire from the company effective October 1, 2024. Shashank Deshpande, currently overseeing the animal health business unit, will assume leadership of the human pharma division starting October 1, 2024. Deshpande joined the board on September 1, 2023.
Dr. Armin Wiesler, the regional managing director and head of animal health for Southeast Asia, Korea, Australia, and New Zealand, will join the board of managing directors effective October 1, 2024. He will take over from Shashank Deshpande in leading the animal health business unit.
Christian Boehringer, chairman of the Shareholders’ Committee, expressed gratitude to Carinne Brouillon: “We extend our sincere thanks to Carinne for her leadership and her efforts in evolving our human pharma business to ready it for our upcoming pipeline launches. Her positive attitude and patient-first approach have been deeply valued”.
Hubertus von Baumbach, chairman of the board of managing directors, commented: “We appreciate Shashank’s acceptance of his new role. His extensive board experience, leadership in key human pharma markets, and marketing expertise make him an ideal successor to Carinne. We also warmly welcome Armin to our board. His deep knowledge of the animal health sector and commercial acumen will support the continuation of the transformative work initiated by Shashank”.
Shashank Deshpande joined Boehringer Ingelheim in 2012 and has previously served as country managing director in Japan, along with holding various leadership and marketing positions in Japan and Germany. Deshpande has a Master’s degree in Business Administration from the University of Hamburg, Germany.
Armin Wiesler, who has been with the company since 2008, has held various local, regional, and global roles, including general manager in Thailand and positions at Boehringer’s US headquarters. He holds a Doctorate and a Master’s degree in Economics from the University of Freiburg, Germany.
Boehringer Ingelheim continues to focus on developing breakthrough therapies that aim to transform lives now and in the future, driven by innovation in areas of high unmet medical need.